Written Question·Department of Health and Social Care·UIN 80726
Selective Serotonin Reuptake Inhibitors: Labelling and Packaging
Tabled: 10 October 2025
Answered: 20 October 2025
Question
Claire Hazelgrove
Labour — Filton and Bradley Stoke
To ask the Secretary of State for Health and Social Care, what discussions he has had with Selective Serotonin Reuptake Inhibitors (SSRIs) manufacturers on the effectiveness of the packaging and labelling of SSRIs in warning patients of (a) the associated
Answer
Dr Zubir AhmedThe Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that selective serotonin reuptake inhibitor (SSRI) packaging and labelling produced by marketing authorisation holders (MAHs) reflects what is known about the safet...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 80726) →